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Background: The therapeutic strategies for malignant melanoma are still cancer chemotherapy, 
radiotherapy, and tumor resection. However, these therapeutic strategies often lead to a reduced 
neutrophilic granulocyte count or loss of more blood after surgical tumor resection. In this study, 
we developed a formulation of hemostatic gauze impregnated with sustained-release granulocyte 
colony-stimulating factor (G-CSF) with increasing of the neutrophilic granulocyte count in the 
blood following chemotherapy and decreasing blood loss after surgical tumor resection.
Methods: We designed a formulation with both hemostatic properties and increased neutrophil 
content to be used in cancer chemotherapy, radiotherapy, and tumor resection, comprising a 
hemostatic gauze as a scaffold and (G-CSF)-loaded dextran nanoparticles coated with polylactic-
co-glycolic acid (PLGA) solution fabricated by direct spray-painting onto the scaffold and then 
vacuum-dried at room temperature. The performance of this system was evaluated in vitro and 
in vivo.
Results: Nearly zero-order release of G-CSF was recorded for 12–14 days, and the cumulative 
release of G-CSF retained over 90% of its bioactivity in a NFS-60 cell line proliferation assay 
when the scaffold was incubated in phosphate-buffered saline (pH 7.4) at 37°C. The in vivo 
hemostatic efficacy of this formulation was greater than that of native G-CSF, the scaffold 
directly spray-painted with G-CSF solution or PLGA organic solution as a coating, or when a 
blank scaffold was covered with the coating.
Conclusion: Our results suggest that this formulation has both hemostatic properties and 
increased neutrophil activity.
Keywords: hemostatic gauze scaffold, granulocyte colony-stimulating factor, bioactivity, 
sustained-release, stability
Introduction
Granulocyte colony-stimulating factor (G-CSF)1 is a member of a family of secreted 
glycoproteins which act on both neutrophils and granulocyte precursors in the bone 
marrow to promote their differentiation, proliferation, and maturation, to mobilize 
neutrophils from the bone marrow pool into the peripheral blood circulation, and 
to control neutrophil dynamics in the blood.2 G-CSF has been investigated as a 
neuroprotective agent in neurological disorders3–7 and has been used clinically to 
increase neutrophil levels in bone marrow transplantation,8 to aid recovery of the 
neutrophil count in treatment of ritodrine-induced neutropenia,9 as an adjunct to 
chemotherapy or radiotherapy in the treatment of cancer,10–13 and in various conditions, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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including neutropenia associated with aplastic anemia or 
myelodysplastic syndrome.
However, cancer chemotherapy and radiotherapy often 
lead to a reduced neutrophilic granulocyte count, and G-CSF 
is used first-line for increasing neutrophilic granulocytes in 
the blood.13 Clinical application of G-CSF involves frequent 
injections, and compliance is poor. In order to enhance 
compliance, the development of noninvasive dosage routes, 
including nasal,14–16 pulmonary,17–19 and oral20–22 formulations 
is expected, and investigations have been performed using 
various formulations, but the bioavailability of these has 
been very low, so they have met with little success.23,24 
A long-acting injectable formulation enabling decreased 
dosing frequency, PEGylated G-CSF, fusion G-CSF protein, 
and sustained-release formulations have also been studied.25–27 
However, PEGylation and fusion protein often causes G-CSF 
bioactivity to decrease, and sustained-release formulations 
suffer from loss of bioactivity and increased immunogenicity 
due to the methods used in their preparation, eg, a shortage 
of protective protein, oil-water or water-air interfaces of 
water-in-oil (w/o),28 water-in-oil-in-water (w/o/w), or water-
in-oil-in-oil (w/o/o) emulsion methods.29–31 We developed 
several novel methods for preserving bioactivity of the protein 
by avoiding creation of oil-water or water-air interfaces, such 
as a stable aqueous-aqueous phase (“emulsion”) and a low-
temperature aqueous-aqueous phase separation method for 
protein-loaded dextran nanoparticles or microparticles.32,33 
These nanoparticles or microparticles may be used further to 
prepare sustained-release formulations.34–36 For example, the 
particles may be used to coat stents, scaffolds, and medical 
devices. Because hemostatic gauze is often used following 
tumor resection or in other diseases to stop bleeding, we 
wanted to develop a formulation of hemostatic gauze 
impregnated with sustained-release G-CSF. We hoped that 
the formulation would increase the neutrophilic granulocyte 
count in the blood following chemotherapy and decrease 
blood loss after surgical tumor resection.
The objective of this study was to develop a surgical 
hemostatic gauze scaffold with high encapsulating efficiency, 
preserved protein stability, and ability to release G-CSF in 
a sustained manner, by loading a hemostatic gauze scaffold 
with G-GSF-dextran nanoparticles and coating the scaffold 
with a polylactide-co-glycolic acid (PLGA) suspension. 
The formulation was characterized by scanning electron 
microscopy, size-exclusion chromatography-high-pressure 
liquid chromatography (HPLC), in vitro release characteristics, 
a NSF-60 cell proliferation assay, and in vivo efficacy.
Materials and methods
Materials
PLGA (50:50, molecular weight 47 kDa; 50:50, molecular 
weight 20 kDa) was obtained from Lakeshore BioMaterials 
Inc (Kent, OH). Hemostatic gauze (oxidized regenerated 
cellulose) was purchased from Ethicon SARL (Neuchatel, 
Switzerland). Ethyl acetate (analytical reagent), dichlo-
romethane (analytical reagent), dextran (molecular weight 
64,000–76,000, biochemical reagent) and polyethylene 
glycol (PEG, molecular weight 6000, biochemical reagent) 
were purchased from Sigma-Aldrich (St Louis, MO). G-CSF 
was supplied by Jinsai Yaoye Co Ltd (Changchun, China). 
A human G-CSF enzyme-linked immunosorbent assay kit 
was purchased from R&D Systems Inc (Minneapolis, MN). 
A bipotential murine hemopoietic cell line (NFS-60) was 
purchased from the American Type Culture Collection 
(Manassas, VA).
Animals
Adult male Sprague Dawley rats weighing approximately 
200 g were used. The animals were maintained under 
standardized rodent conditions at a room temperature of 
22°C ± 1°C. The animal experiments complied with the 
principles of laboratory animal care and were approved by 
the Institutional Animal Care and Utilization Committee of 
Shanghai Jiao Tong University.
g-csF-loaded dextran nanoparticles
A 3 mL mixture of dextran (1%, w/w), G-CSF (0.25%, 
w/w), and PEG (5%, w/w) in a ratio of 1:4:20 was 
prepared,32 and then frozen in a refrigerator at -80°C 
overnight. Samples were lyophilized using a Christ Alpha 
1–2 laboratory freeze-dryer at a pressure of 5.25 × 10–3 Pa 
for 24 hours. The lyophilized powders were washed with 
5 mL of dichloromethane, then centrifuged at 12,000 rpm 
for 5 minutes (Eppendorf 5415D, Hamburg, Germany) 
to remove the supernatant liquid, ie, the PEG continuous 
phase (because G-CSF-loaded dextran nanoparticles are 
insoluble in dichloromethane and would precipitate in the 
bottom of the centrifuge tube). The washing-centrifugation 
procedure was repeated three times, and the G-CSF dextran 
nanoparticles collected were evaporated at 1.33 Pa and 
room temperature for 24 hours using a vacuum dryer 
(Fuma DZF-3, Shanghai Fuma Co Ltd, Shanghai, China) 
to remove the dichloromethane residue. The nanoparticles 
obtained contained less than 0.5% (w/w) PEG after the 
washing process.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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hemostatic gauze scaffold  
with g-gsF-loaded dextran nanoparticles
The hemostatic gauze scaffold containing G-GSF-loaded 
dextran nanoparticles was prepared by spraying and painting 
a 2.5 cm × 1 cm piece of hemostatic gauze scaffold with a 
suspension containing G-CSF-loaded dextran nanoparticles 
and PLGA ethyl acetate solution or G-CSF in aqueous 
solution and PLGA ethyl acetate solution at a rate of 
0.25 mL/minute. The suspension was prepared by vortex 
mixing 5% PLGA ethyl acetate solution (containing 20 mg 
PLGA) and 5 mg G-CSF-loaded dextran nanoparticles 
for 5 minutes. After initial drying, the hemostatic gauze 
scaffold with G-CSF-loaded dextran nanoparticles was put 
in a refrigerator at 20°C for at least 10 hours, followed by 
further evaporation at room temperature in a vacuum below 
0.1 mbar for 48 hours to remove any dichloromethane residue. 
The hemostatic gauze scaffold containing G-CSF-loaded 
dextran nanoparticles was then sprayed and painted with 
additional G-CSF dextran nanoparticle-free PLGA (14 mg), 
with the outer layer free of dextran nanoparticles to improve 
the release kinetics of G-CSF.
After the hemostatic gauze scaffold containing G-CSF-
loaded dextran nanoparticles had been refrigerated at -20°C 
and freeze-dried for 10 hours, the pure hemostatic gauze 
scaffold was attached and adhered to the surface of the 
hemostatic gauze scaffold containing G-CSF-loaded dextran 
nanoparticles and further evaporated in a vacuum below 
0.1 mbar for 48 hours to remove any dichloromethane residue 
at room temperature.
scanning electron microscopy
Scanning electron microscopy (SEM) images of the 
hemostatic gauze, hemostatic gauze scaffold containing 
G-CSF-loaded dextran nanoparticles, and the G-CSF 
dextran nanoparticles alone were obtained using a FEI 
Sirion 200 SEM (Hillsboro, OR). Prior to image scanning, 
the samples were coated with gold vapor under an argon 
atmosphere and at 5–10 keV .
size distribution of g-csF dextran 
nanoparticles
The size distribution and average particle size of the G-CSF 
dextran nanoparticles were detected using a particle size and 
shape analyzer (Ankersmid CIS-100, Edegem,   Belgium). 
Ten milligrams of dry particles were resuspended in a 
quartz cell containing isopropyl alcohol with a stirring 
magnet bar.
G-CSF encapsulation efficiency
The hemostatic gauze scaffold containing G-CSF-loaded 
dextran nanoparticles was washed with 10 mL dichlo-
romethane, and then centrifuged at 12,000 rpm for 5 minutes 
to remove the PLGA and recover the G-CSF-loaded dextran 
nanoparticles, which were then redissolved in phosphate-
buffered saline (pH 7.4) and diluted using a G-CSF enzyme-
linked immunosorbent assay kit. The G-CSF encapsulation 
efficiency of the hemostatic gauze scaffold with G-CSF-
loaded dextran nanoparticles was determined using the 
following equation:
  Encapsulation efficiency (%) = P/Pt × 100
where P is the actual total weight of G-CSF encapsulated 
into the coating on the scaffold and Pt is the theoretical 
amount of G-CSF (obtained from feeding) encapsulated 
into the coating. The standard deviation for drug loading 
was calculated based on the coating experiments which were 
repeated five times.
size exclusion chromatography
Size exclusion chromatography was carried out using a 
HPLC system equipped with a TSK G2000SWXL size 
exclusion column (Shimadzu, Tokyo, Japan). Elution was 
performed using a peristaltic pump with 50 mM phosphate-
buffered saline (pH 7.3) and a flow rate of 1.0 mL/minute 
at room temperature. Absorbance of each sample was 
measured at a wavelength of 214 nm. The dissolved G-CSF 
sample was filtered using a 0.22 µm film and then injected 
into the HPLC system. The flow rate of the mobile phase 
was 1.0 mL/minute. The amount of monomer or aggregate 
G-CSF was calculated using the Chromato-Solution-Light 
Shimadzu software.
In vitro release profile
The 2.5 cm × 1 cm hemostatic gauze scaffolds containing 
G-CSF-loaded dextran nanoparticles (18 mg) were 
individually incubated in vials containing 2 mL of phos-
phate-buffered saline (100 mM, pH 7.4) at 37°C under 
constant shaking. For G-CSF release, the release medium 
was replaced by fresh buffer on a scheduled date and the 
G-CSF contents were assayed using a G-CSF enzyme-
linked immunosorbent assay kit. For each sample, the 
G-CSF release experiment was repeated five times and 
release profiles were calculated based on the average of 
three experiments.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In vitro release bioactivity
A NFS-60 cell line were cultured in RPMI 1640 (Gibco®, 
Invitrogen, Carlsbad, CA) with 10% fetal calf serum and 
5 ng/mL G-CSF. Prior to the assays, exponentially growing 
cells were washed free of G-CSF and resuspended in 
RPMI 1640 with 5% fetal calf serum. Samples containing 
5 × 104 cells were incubated in 100 mL of RPMI 1640 with 
10% fetal calf serum containing solution released from 
hemostatic gauze scaffold containing G-CSF-loaded dextran 
nanoparticles. After 48 hours, growth of NFS-60 cells was 
determined using the MTT method.37
In vivo release study
Five male Sprague Dawley rats (6 weeks old, average 
weight 200 g) underwent subcutaneous implantation of a 
hemostatic gauze scaffold loaded with native G-CSF dextran 
nanoparticles, a G-CSF-loaded hemostatic gauze scaffold 
using native G-CSF solution and PLGA suspension, or a 
pure hemostatic gauze scaffold at 0.15 mg/kg. A 0.4 mL 
blood sample was collected using a heparinized syringe from 
each animal at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 15 days after 
implantation. The blood samples were centrifuged at rate of 
12,000 rpm at 4°C for 20 minutes, and then plasma samples 
were collected. Plasma G-CSF levels were determined using 
a G-CSF enzyme-linked immunosorbent assay kit.
In vivo efficacy study
For the in vivo efficacy study, 6-week-old Sprague 
Dawley rats underwent subcutaneous implantation of a 
hemostatic gauze scaffold containing G-CSF-loaded   dextran 
nanoparticles, a hemostatic gauze scaffold loaded with 
native G-CSF solution and PLGA suspension, a subcutane-
ous injection of native G-CSF solution at 0.15 mg/kg, or 
physiological saline. A 0.2 mL blood sample was collected 
from each rat using a heparinized syringe at 1, 2, 3, 4, 5, 6, 7, 
8, 10, 12, and 15 days after administration. Neutrophil counts 
were determined as described previously.38 The percentage 
of neutrophils was determined using a complete blood count 
(Beckman Coulter LH, Fullerton, CA), and the increasing 
ratio of neutrophils per µL of blood was measured using 
the neutrophil percentage of G-CSF samples divided by 
neutrophil percentage of physiological saline samples.
To observe the hemostatic efficacy of the hemostatic gauze 
scaffold containing G-CSF-loaded dextran nanoparticles, 
we implanted three pieces of hemostatic gauze scaffold, 
ie, one piece of pure hemostatic gauze scaffold, one piece 
containing G-CSF-loaded dextran nanoparticles, and a piece 
of pure hemostatic gauze scaffold adhered to the surface of a 
hemostatic gauze scaffold containing G-CSF-loaded dextran 
nanoparticles, and then measured the time to hemostasis.
statistical analysis
The data were expressed as the mean ± standard deviation, 
and statistically significant differences were sought using the 
Student’s t-test. P , 0.05 was considered to be statistically 
significant. Statistical analyses were carried out using SPSS 
software (SPSS Inc, Chicago, IL).
Results
Morphology and size distribution
The morphology of the samples was characterized using SEM 
and an Olympus µ710 camera. Figure 1 shows the morphol-
ogy of the hemostatic gauze scaffolds containing different 
coatings at different release times. We found that the implants 
started to degrade on day 2 and the hemostatic gauze in the 
scaffold implants was completely broken down by day 7.39 
Figure 2F, G, and H confirm this finding. Figure 2A and B 
are images for G-CSF-loaded dextran nanoparticles alone 
and G-CSF-loaded dextran nanoparticles recovered from the 
scaffold, respectively. The results show that the surfaces of 
both G-CSF-loaded dextran nanoparticles alone and those 
recovered from the scaffold were smooth and nonporous, with 
the same size and morphology. Figure 2C and D are images for 
a blank hemostatic gauze scaffold and a scaffold containing 
G-CSF-loaded dextran nanoparticles, respectively. The hemo-
static gauze scaffold had a fibrous structure in which groups 
of fine fibers formed larger bundles of fibers. The hemostatic 
gauze scaffold containing G-CSF-loaded dextran nanopar-
ticles regardless of 5% G-CSF-loaded dextran nanoparticles 
Figure 1 hemostatic gauze scaffold implants. (A) Implant, (B) release on day 1,   
(C) release on day 2, and (D) release on day 7.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and PLGA lead to complete coverage of the tops of the fiber 
bundles, and as a result, the fibrous structure became invisible 
(Figure 2D). A cross-section of a hemostatic gauze scaffold 
containing G-CSF-loaded dextran nanoparticles showed that 
the nanoparticles and PLGA   contained gaps (Figure 2E). 
Figure 2F, G, and H showed that the scaffold itself degraded and 
became more porous. The mean diameter of the G-CSF-loaded 
dextran nanoparticles was 100 ± 20 nm, with the majority of 
nanoparticles ranging from 60 to 100 nm.
G-CSF encapsulation efficiency from 
coating of hemostatic gauze implants
G-CSF encapsulation efficiency was measured using a 
human G-CSF enzyme-linked immunosorbent assay kit. 
The encapsulation efficiency of the first-step particles, ie, 
loading the proteins into the dextran nanoparticles, was 
above 95% (w/w),32 and also for the subsequent two steps. 
The G-CSF loading yield was 96% for the samples projecting 
1% G-CSF loads (ie, G-CSF reached 1% of the total mass 
of the coating material).
Aggregation study in hemostatic gauze 
scaffolds containing g-csF-loaded 
dextran nanoparticles
Formation of protein aggregates gives a good indication of 
protein integrity during the microencapsulation process.40 
Therefore, we assayed the samples using size-exclusion 
chromatography-HPLC in order to determine any change 
in G-CSF with the different procedures. Figure 3 shows the 
size-exclusion chromatography-HPLC results for G-CSF 
aggregation after each preparation step. Figure 3A, B, C, 
and D show the monomer contents of the original G-CSF 
solution, G-CSF from the dextran nanoparticles, recovery 
from hemostatic gauze scaffold containing G-CSF-loaded 
dextran nanoparticles, and from hemostatic gauze scaffold 
loaded directly with G-CSF solution and PLGA suspension, 
respectively. The monomer content of G-CSF did not decrease 
during the coating process compared with the original sample, 
except that the monomer content of G-CSF in the hemostatic 
gauze scaffold loaded with G-CSF decreased by 20%. These 
results strongly suggest that the implant preparation process 
used in the present study is a useful method for coating hemo-
static gauze scaffold implants without aggregation.
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Figure 2 scanning electron micrographs of different samples (A) g-csF dextran 
nanoparticles,  (B)  g-csF  dextran  nanoparticles  from  hemostatic  gauze  scaffold 
containing g-csF-loaded dextran nanoparticles, (C) blank hemostatic gauze scaffold, 
(D) hemostatic gauze scaffold containing g-csF-loaded dextran nanoparticles, and 
(E) cross-section from hemostatic gauze scaffold containing g-csF-loaded dextran 
nanoparticles. (F) release on day 1, (G) release on day 2, and (H) release on day 7. 
Abbreviation: g-csF, granulocyte-colony stimulating factor.
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Figure 3 Monomer content of recovery g-csF from the scaffold by size exclusion 
chromatography-high pressure liquid chromatography (n = 5, *P . 0.05, **P , 0.05). 
(A) g-csF (g-csF:dextran = 1.4:5.0 ± 0.3 mg) solution; (B) g-csF from g-csF-
loaded dextran nanoparticles; (C) g-csF from hemostatic gauze scaffold containing 
G-CSF-loaded dextran nanoparticles (PLGA 50/50 3A: first coating = 20.0 ± 0.5 mg 
PLgA, g-csF-loaded dextran nanoparticles (g-csF:dextran, 1:4) = 5.0 ± 0.3 mg, 
second coating (blank) = 14.0 ± 0.6 mg PLgA); (D) g-csF from hemostatic gauze 
scaffold  containing  G-CSF-loaded  dextran  nanoparticles  (PLGA  50/50  3A:  first 
coating = 20.0 ± 0.5 mg PLgA, g-csF solution [g-csF:dextran = 1:4] = 5.0 ± 0.3 mg, 
second coating [blank] = 14.0 ± 0.6 mg PLgA). 
Abbreviations: g-csF, granulocyte-colony stimulating factor; PLgA, polylactic-
co-glycolic acid.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3144
Yuan and Liu
Bioactivity of hemostatic gauze scaffold 
containing g-csF-loaded dextran 
nanoparticles
In order to determine the bioactivity of the different 
samples, G-CSF was recovered from the formulations 
according to the method used for determination of G-CSF 
encapsulation efficiency. The bioactivity of G-CSF was 
assayed using the NFS-60 cell line. Figure 4 shows 
the bioactivity of G-CSF from the different samples, 
  respectively. Figure 4A, B, and C shows the bioactivity of 
the original G-CSF solution, G-CSF from G-CSF-loaded 
dextran nanoparticles, and G-CSF from the hemostatic 
gauze scaffold containing G-CSF-loaded dextran nanopar-
ticles (PLGA 50/50 3A), respectively. We found that the 
bioactivity of the samples was almost the same as for the 
original G-CSF solution (P . 0.05). Figure 4D, E, and F 
show the bioactivity of G-CSF from a hemostatic gauze 
scaffold containing G-CSF-loaded dextran nanoparticles 
(PLGA 50/50 1A), a hemostatic gauze scaffold loaded 
with G-CSF solution (PLGA 50/50 3A), and a hemostatic 
gauze scaffold loaded directly using G-CSF solution and 
PLGA suspension (PLGA 50/50 1A), respectively. The 
results show that the recovered bioactivity of G-CSF from 
a hemostatic gauze scaffold containing G-CSF-loaded dex-
tran nanoparticles (PLGA 50/50 1A), a hemostatic gauze 
scaffold loaded with G-CSF solution and PLGA suspension 
(PLGA 50/50 3A and PLGA 50/50 1A, respectively) was 
decreased by 17%, 55%, and 60%, respectively (P , 0.05). 
The recovered bioactivity suggested that the G-CSF in 
the G-CSF-loaded dextran nanoparticles had been well 
protected during the preparation process. This is probably 
because G-CSF-loaded dextran nanoparticles might avoid 
oil-water and water-gas interfaces which result in loss of 
G-CSF bioactivity.31
release kinetics for hemostatic gauze 
scaffold containing g-csF-loaded dextran 
nanoparticles
Figure 5A and B summarize the G-CSF release profiles 
for hemostatic gauze scaffolds containing PLGA coatings 
of different molecular weights. Interestingly, as shown 
in Figure 5, the two samples showed a similar zero order 
G-CSF release profile regardless of molecular weight (release 
kinetics equations: QA = 12.574t + 9.4172, R2 = 0.9705 and 
QB = 8.90003t + 7.4446, R2 = 0.962, from day 1 to day 7), 
but the amount of cumulative release was less from the low 
molecular weight polymer than from the high molecular 
weight polymer. We reported the result of the degradation 
study by plotting the weight of each formulation against the 
release incubation time at 37°C. When a piece of hemostatic 
gauze scaffold containing no coating (2.5 cm × 1 cm, 18 mg) 
was incubated in 2 mL of phosphate-buffered saline at 37°C, 
the total mass completely disappeared within 3 days.39 As 
shown in Figures 1, 2F, G, and H, hemostatic gauze scaf-
folds coated with G-CSF-loaded dextran nanoparticles and 
a PLGA layer of different molecular weights or with an 
additional blank PLGA layer all broke down during the same 
time period, suggesting that the rate of release of G-CSF 
0
A
%
 
r
e
l
a
t
i
v
e
 
b
i
o
a
c
t
i
v
i
t
y
BCDEF
* ****
** **
20
40
60
80
100
120
Figure 4 recovery bioactivity from a hemostatic gauze scaffold containing g-csF-loaded dextran nanoparticles (n = 5, *P . 0.05, **P , 0.05). samples (A), (B), (C), 
and (E) were the same as for Figure 3A, B, c, and D, respectively (n = 5, *P . 0.05, **P , 0.05). (D) hemostatic gauze scaffold containing g-csF from g-csF-loaded 
dextran nanoparticles (PLGA 50/50 1A: first coating = 20.0 ± 0.6 mg PLgA, g-csF loaded-dextran nanoparticles [g-csF: dextran = 1:4] = 5.0 ± 0.2 mg, second coating 
[blank] = 14.0 ± 0.5 mg PLgA), (F) G-CSF from hemostatic gauze scaffold containing G-CSF-loaded dextran nanoparticles (PLGA 50/50 1A: first coating = 20.0 ± 0.6 mg 
PLgA, g-csF solution [g-csF:dextran = 1:4] = 5.0 ± 0.2 mg, second coating [blank] = 14.0 ± 0.5 mg PLgA). 
Abbreviations: g-csF, granulocyte-colony stimulating factor; PLgA, polylactic-co-glycolic acid.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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was due to degradation of the hemostatic gauze scaffold and 
independent of the PLGA coating. When G-CSF solution was 
loaded into hemostatic gauze scaffold using PLGA coating, 
the percentage cumulative release was only 30%–40%. This 
was probably because the spraying and painting process 
produced a number of oil-water and gas-water interfaces, 
resulting in G-CSF aggregation and more hydrophobicity, 
with no release of G-CSF.31
In vitro g-csF release bioactivity  
in hemostatic gauze scaffold containing 
g-csF-loaded dextran nanoparticles
The bioactivity of in vitro release from hemostatic gauze 
scaffolds containing G-CSF-loaded dextran nanoparticles 
was investigated using the NFS-60 cell line. Figure 6A 
and B show that the bioactivity of release of G-CSF from 
hemostatic gauze scaffolds containing G-CSF-loaded dex-
tran nanoparticles (PLGA 50/50 3A and PLGA 50/50 1A) 
showed high efficiency. The release bioactivity percent of 
G-CSF on the first day was 20% of the cumulative release 
bioactivity of G-CSF, and the percent of cumulative release 
bioactivity was about 80%–96% of the total bioactivity 
within the scaffold coating. When the G-CSF solution was 
loaded into hemostatic gauze scaffolds with PLGA coating, 
the percent cumulative release bioactivity of G-CSF was 
only 30%–40%. This was probably because the spraying 
and painting process produced a number of oil-water and 
gas-water interfaces resulting in G-CSF aggregation and 
more hydrophobicity.31
release of g-csF in an in vivo rat study
We examined the release of G-CSF from the G-CSF-loaded 
dextran nanoparticles and from a hemostatic gauze scaffold 
loaded directly using G-CSF solution and PLGA suspension, 
because the G-CSF released is only bioactive in vivo.   Figure 7 
◊ and ♦ show the plasma G-CSF concentration-time release 
profiles for G-CSF-loaded dextran nanoparticles and hemo-
static gauze scaffold loaded directly with G-CSF solution and 
PLGA suspension, respectively. The results showed a stable 
plasma concentration from days 1 to 7, and then slow release 
of G-CSF up to day 15 from hemostatic gauze scaffolds 
containing G-CSF-loaded dextran nanoparticles. However, 
scaffolds loaded directly with G-CSF solution and PLGA 
suspension did not show stable plasma concentrations, with 
fast release of G-CSF from day 1 to day 3, and no G-CSF 
release thereafter. This confirms that the hemostatic gauze 
scaffold containing G-CSF-loaded dextran nanoparticles 
was more effective than the scaffold containing the directly 
loaded G-CSF solution.
In vivo efficacy study
To compare the in vivo efficacy of scaffolds containing 
G-CSF-loaded dextran nanoparticles, scaffolds containing 
directly loaded G-CSF solution, pure scaffolds, and native 
G-CSF alone, male Sprague Dawley rats underwent 
subcutaneous implantation with scaffolds loaded with 
dextran nanoparticles, scaffolds loaded with G-CSF, pure 
scaffolds, or subcutaneous injection of native G-CSF at 
0.15 mg/kg. Changes in neutrophil count were determined 
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for 15 days. The time courses in Figure 8 , ◊, and ♦ 
show that scaffolds containing G-CSF-loaded dextran 
nanoparticles or G-CSF solution achieved a significant 
increase in neutrophil count for a prolonged period of time, 
but the increasing ratio of neutrophil count and prolonged 
time from G-CSF solution-loaded the scaffold were more 
than G-CSF solution-loaded the scaffold (the pure scaf-
fold did not show an increase in neutrophil count, data 
not shown).
We found that the time to hemostasis for the scaffold 
containing G-CSF-loaded dextran nanoparticles was longer 
than that for the same-sized pure hemostatic gauze scaffold 
and pure hemostatic gauze scaffold adhered to a scaffold 
loaded with dextran nanoparticles. However, the time to 
hemostasis from both a pure hemostatic gauze scaffold and 
a pure hemostatic gauze scaffold adhered to the surface of 
a scaffold loaded with dextran nanoparticles was almost 
the same (P , 0.05). This suggests that the scaffold loaded 
with dextran nanoparticles might work for both increasing 
the neutrophil count and stopping bleeding when the pure 
hemostatic gauze scaffold was attached and adhered to the 
surface of a scaffold loaded with dextran nanoparticles.
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Figure 6 In vitro release relative bioactivity of hemostatic gauze scaffold containing g-csF-loaded dextran nanoparticles (n = 5, P , 0.05). samples (A), (B), (C), and (D) 
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Discussion
A zero order release profile for G-CSF was observed from the 
scaffolds containing G-CSF-loaded dextran nanoparticles, 
regardless of the molecular weight of the PLGA coating 
used from days 1 to 7 (Figures 5A and B). This finding sug-
gests that the rate-limiting step for G-CSF release was not 
just controlled by PLGA, but by other factors, including the 
dextran nanoparticles and the scaffold. The pure scaffold 
is easily degraded, taking 1–2 weeks to break down into 
molecular pieces (http://store.k12webstore.com/mkgz24.
html), and dextran nanoparticles also absorb water and 
swell.43 These observations suggest that pores or holes in 
the surface of the PLGA coating can be created when a pure 
hemostatic gauze scaffold with PLGA is degraded and broken 
fragments form.39 Rapid degradation of the hemostatic gauze 
scaffold creates sufficient penetration of water diffusion chan-
nels for G-CSF release of all implants coated with PLGA of 
different molecular weights.39 At the same time, the G-CSF 
diffusion distance from the inner to outer coating decreases 
due to swelling of the dextran nanoparticles through absorp-
tion of water compared with no swelling additives.42
These resulting in that at the beginning of the release 
phase, G-CSF were near the coating surface of the G-CSF-
loaded dextran nanoparticle scaffolds, then the hemostatic 
gauze scaffold started to degrade and formed more and more 
new holes in the coating that led to water being permeated 
into the coating and increased diffusion of G-CSF and dextran 
swelling (of course, finally dextran also was dissolved and 
diffused, the PLGA also was degraded, but PLGA degraded 
slower than the pure scaffold during the whole release 
process). With these diffusion channels, the diffusion rate 
of G-CSF became significantly higher than that of high 
molecular weight dextran, thus the overall release rate 
was limited by the swelling of dextran. Figure 2F–H also 
confirmed the process.39 The linear release from the G-CSF-
loaded dextran nanoparticle scaffold appeared attributable to 
the above effects.44–46
Figures 5A and B, 6A and B also show that the degra-
dation rate of PLGA did not affect the release rate or cell 
proliferation activity of the G-CSF released or the cumulative 
amount released from the scaffolds containing G-CSF-loaded 
dextran nanoparticles. The cumulative amount released from 
scaffolds containing G-CSF-loaded dextran nanoparticles 
with PLGA of higher molecular weight was more than that of 
PLGA of lower molecular weight. This was possibly because 
G-CSF was unstable in a locally acidic environment, 41,43 in 
which the degradation rate of lower molecular weight PLGA 
was faster than for higher molecular weight PLGA which, in 
turn, formed a more acidic local environment.41,43 Figure 5C 
and D show further release kinetic profiles which were 
probably because G-CSF had aggregated and become more 
hydrophobic, resulting in no release of G-CSF,43 suggesting 
that the spray-painted coatings had produced a number of 
oil-water and gas-water interfaces.31
In order to understand the mechanism of the scaffold, a 
pure hemostatic gauze scaffold was attached and adhered to 
the surface of a hemostatic gauze scaffold containing G-CSF-
loaded dextran nanoparticles for study of in vitro and in vivo 
release. We found that the release profile, plasma G-CSF 
level, and increase in neutrophil count were the same for a 
hemostatic gauze scaffold containing G-CSF-loaded dextran 
nanoparticles (data no shown), but that the time to hemostasis 
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was shorter. This suggested that the pure hemostatic gauze 
scaffold does not affect the activity of the G-CSF-loaded 
dextran nanoparticle scaffold in terms of release of G-CSF, 
but may improve hemostasis activity.
By coating the gauze scaffold with G-CSF-loaded dextran 
nanoparticles and PLGA suspension, sustained-release delivery 
of the drug can be achieved easily. In addition, the desired 
release kinetics, such as a low level of initial burst release and a 
zero order release profile can also be easily achieved. With the 
right thickness, the G-CSF-loaded dextran nanoparticle-free 
top layer of PLGA may provide additional control of G-CSF 
release mechanisms. The PLGA coating on the hemostatic gauze 
scaffold can easily be attached and applied to the wound surface 
during surgery to stop post-surgical bleeding and to improve 
the neutrophilic granulocyte count in blood during chemotherapy 
as well as to staunch bleeding after tumor resection.
Conclusion
Using a clinically available hemostatic agent as a scaffold, 
we demonstrated that a hemostatic gauze scaffold containing 
G-CSF-loaded dextran nanoparticles can achieve controlled 
delivery of G-CSF. G-CSF were released from this formula-
tion through a mechanism of diffusion channels independent 
of G-CSF-loaded different molecular weight PLGA that was 
created due to rapid degradation of the hemostatic gauze 
scaffold inside the PLGA coating and dextran microparticle 
swelling. Such diffusion channels could be blocked by an 
additional coating of G-CSF-loaded dextran nanoparticle-
free PLGA to reach the desired G-CSF release rate. In 
addition to nearly zero order and burst-free release kinetics, 
this formulation approach was simple and did not require a 
complicated microencapsulation process, thus could easily 
be scaled up and potentially used to improve the neutrophilic 
granulocyte level in blood at the time of chemotherapy and 
staunch bleeding after tumor resection.
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